BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34420893)

  • 1. Management and Outcome of Coronavirus Disease 2019 (COVID-19) in Pediatric Cancer Patients: A Single Centre Experience from a Developing Country.
    Hammad M; Shalaby L; Sidhom I; Sherief N; Abdo I; Soliman S; Madeny Y; Hassan R; Elmeniawy S; Khamis N; Zaki I; Mansour T; El-Ansary MG; Al-Halfawy A; Abouelnaga S; Elhaddad A
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e853-e864. PubMed ID: 34420893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study.
    Węcławek-Tompol J; Zakrzewska Z; Gryniewicz-Kwiatkowska O; Pierlejewski F; Bień E; Zaucha-Prażmo A; Zając-Spychała O; Szmydki-Baran A; Mizia-Malarz A; Bal W; Sawicka-Żukowska M; Kruk A; Ociepa T; Raciborska A; Książek A; Szczepański T; Peregud-Pogorzelski J; Krawczuk-Rybak M; Chaber R; Matysiak M; Wachowiak J; Irga-Jaworska N; Młynarski W; Dembowska-Bagińska B; Balwierz W; Matkowska-Kocjan A; Kazanowska B; Styczyński J; Ussowicz M
    J Hematol Oncol; 2021 Oct; 14(1):163. PubMed ID: 34635137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compassionate use of remdesivir in children with COVID-19.
    Méndez-Echevarría A; Pérez-Martínez A; Gonzalez Del Valle L; Ara MF; Melendo S; Ruiz de Valbuena M; Vazquez-Martinez JL; Morales-Martínez A; Remesal A; Sándor-Bajusz KA; Cabañas F; Calvo C
    Eur J Pediatr; 2021 Apr; 180(4):1317-1322. PubMed ID: 33200304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of an Immunocompromised Pediatric Patient With Multiple Hospitalizations for Symptomatic COVID-19.
    DeVine MN; Maxwell S; Haynes AS; MacBrayne CE; Boguniewicz J
    J Pediatr Hematol Oncol; 2022 Jan; 44(1):e293-e295. PubMed ID: 33235142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compassionate Use of Remdesivir in Children With Severe COVID-19.
    Goldman DL; Aldrich ML; Hagmann SHF; Bamford A; Camacho-Gonzalez A; Lapadula G; Lee P; Bonfanti P; Carter CC; Zhao Y; Telep L; Pikora C; Naik S; Marshall N; Katsarolis I; Das M; DeZure A; Desai P; Cao H; Chokkalingam AP; Osinusi A; Brainard DM; Méndez-Echevarría A
    Pediatrics; 2021 May; 147(5):. PubMed ID: 33883243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neonates With SARS-CoV-2 Infection and Pulmonary Disease Safely Treated With Remdesivir.
    Saikia B; Tang J; Robinson S; Nichani S; Lawman KB; Katre M; Bandi S
    Pediatr Infect Dis J; 2021 May; 40(5):e194-e196. PubMed ID: 33847299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Remdesivir in children with COVID-19: report of an Italian multicenter study.
    Romani L; Roversi M; Bernardi S; Venturini E; Garazzino S; Donà D; Krzysztofiak A; Montagnani C; Funiciello E; Calò Carducci FI; Marabotto C; Castagnola E; Salvini F; Lancella L; Lo Vecchio A; Galli L; Castelli Gattinara G;
    Ital J Pediatr; 2024 Feb; 50(1):32. PubMed ID: 38413992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative outcomes of combined corticosteroid and remdesivir therapy with corticosteroid monotherapy in ventilated COVID-19 patients.
    Mandadi S; Pulluru H; Annie F
    PLoS One; 2022; 17(2):e0264301. PubMed ID: 35196344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 10-Year-old Girl With Late Acute Lymphoblastic Leukemia Recurrence Diagnosed With COVID-19 and Treated With Remdesivir.
    Gadzińska J; Kuchar E; Matysiak M; Wanke-Rytt M; Kloc M; Kubiak JZ
    J Pediatr Hematol Oncol; 2022 Mar; 44(2):e537-e538. PubMed ID: 33885040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
    Khazir J; Maqbool T; Mir BA
    Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remdesivir for the Treatment of Severe COVID-19: A Community Hospital's Experience.
    Lee S; Santarelli A; Caine K; Schritter S; Dietrich T; Ashurst J
    J Am Osteopath Assoc; 2020 Dec; 120(12):926-933. PubMed ID: 33136164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remdesivir and corticosteroids in the treatment of hospitalized COVID-19 patients.
    Coelho L; Falcão F; Póvoa P; Viegas E; Martins AP; Carmo E; Fonseca C; Campos L; Mansinho K; Carmo I; Soares J; Solano M; Mendes D; Miranda AC; Carvalho A; Mirco A; Farinha H; Aldir I; Correia J
    Sci Rep; 2023 Mar; 13(1):4482. PubMed ID: 36934143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.
    Humeniuk R; Mathias A; Kirby BJ; Lutz JD; Cao H; Osinusi A; Babusis D; Porter D; Wei X; Ling J; Reddy YS; German P
    Clin Pharmacokinet; 2021 May; 60(5):569-583. PubMed ID: 33782830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Characteristics and Outcomes of Hospitalized and Critically Ill Children and Adolescents with Coronavirus Disease 2019 at a Tertiary Care Medical Center in New York City.
    Chao JY; Derespina KR; Herold BC; Goldman DL; Aldrich M; Weingarten J; Ushay HM; Cabana MD; Medar SS
    J Pediatr; 2020 Aug; 223():14-19.e2. PubMed ID: 32407719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel.
    Goldberg E; Ben Zvi H; Sheena L; Sofer S; Krause I; Sklan EH; Shlomai A
    Clin Microbiol Infect; 2021 Jun; 27(6):917.e1-917.e4. PubMed ID: 33705849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients.
    Weinbergerova B; Mayer J; Kabut T; Hrabovsky S; Prochazkova J; Kral Z; Herout V; Pacasova R; Zdrazilova-Dubska L; Husa P; Bednar P; Ruzek D; Lengerova M
    Hematol Oncol; 2021 Dec; 39(5):715-720. PubMed ID: 34396566
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
    Spinner CD; Gottlieb RL; Criner GJ; Arribas López JR; Cattelan AM; Soriano Viladomiu A; Ogbuagu O; Malhotra P; Mullane KM; Castagna A; Chai LYA; Roestenberg M; Tsang OTY; Bernasconi E; Le Turnier P; Chang SC; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wang H; Gaggar A; Brainard DM; McPhail MJ; Bhagani S; Ahn MY; Sanyal AJ; Huhn G; Marty FM;
    JAMA; 2020 Sep; 324(11):1048-1057. PubMed ID: 32821939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia in a Newborn Treated With Remdesivir and Coronavirus Disease 2019 Convalescent Plasma.
    Hopwood AJ; Jordan-Villegas A; Gutierrez LD; Cowart MC; Vega-Montalvo W; Cheung WL; McMahan MJ; Gomez MR; Laham FR
    J Pediatric Infect Dis Soc; 2021 May; 10(5):691-694. PubMed ID: 33306130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in Treating Pediatric Cancer Patients during the COVID-19 Pandemic: Balancing Risks and Care.
    Chávez-Pacheco JL; Castillejos-López M; Hernández-Regino LM; Velasco-Hidalgo L; Zapata-Tarres M; Correa-Carranza V; Rosario-Méndez G; Barrientos-Ríos R; Aquino-Gálvez A; Torres-Espíndola LM
    Viruses; 2024 Apr; 16(5):. PubMed ID: 38793571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
    Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Poissy J; Belhadi D; Diallo A; Lê MP; Peytavin G; Staub T; Greil R; Guedj J; Paiva JA; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
    Lancet Infect Dis; 2022 Feb; 22(2):209-221. PubMed ID: 34534511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.